Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
2011
First long-term (2-year) controlled study to evaluate treatment with safinamide as add-on to levodopa in patients with Parkinson's disease and motor fluctuations
Anand R, Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Lucini V
63rd AAN Annual Meeting - April 9 to 16 - Honolulu, Hawaii
Safinamide reduces levodopa-induced dyskinesia and extends ON time over 7 days of daily dosing in the MPTP primate model.
Arthur Roach, , Laurent Gregoire, Therese Di Paolo
63rd AAN Annual Meeting - April 9 to 16 - Honolulu, Hawaii